Photocatalytic Activity of TiO2 for the Degradation of Anticancer Drugs

To prevent water pollution, photocatalysis is often used to remove small molecules such as drugs by generating reactive species. This study aimed to determine the photocatalytic activity of two anticancer drugs, imatinib and crizotinib, and to investigate various influences that may alter the kinetic degradation rate and ultimately the efficacy of the process. In order to obtain optimal parameters for the removal of drugs with immobilized TiO2, the mutual influence of the initial concentration of the contaminant at environmentally relevant pH values was investigated using the response surface modeling approach. The faster kinetic rate of photocatalysis was obtained at pH 5 and at the smallest applied concentration of both drugs. The photocatalytic efficiency was mostly decreased by adding various inorganic salts and organic compounds to the drug mixture. Regarding the degradation mechanism of imatinib and crizotinib, hydroxyl radicals and singlet oxygen showed a major role in photochemical reactions. The formation of seven degradation products for imatinib and fifteen for crizotinib during the optimal photocatalytic process was monitored by high-resolution mass spectrometry (HPLC-QqTOF). Since the newly formed products may pose a hazard to the environment, their toxicity was studied using Vibrio fischeri, where the significant luminescence inhibition was assessed for the mixture of crizotinib degradants during the photocatalysis from 90 to 120 min.

Automated summary

Photocatalysis is effective in removing small molecules like anticancer drugs, with faster kinetic rates found at pH 5 and lower drug concentrations. However, the efficiency of photocatalysis can be reduced by the addition of inorganic salts and organic compounds. The degradation mechanism of the drugs involves hydroxyl radicals and singlet oxygen, with potential toxicity of newly formed products needing further study.